Jun. 17 at 5:08 AM
✅ 4:00am EST Watchlist ✅
$VERV – Eli Lilly is reportedly in advanced talks to acquire Verve Therapeutics in an all-stock deal worth up to
$1.3B, including ~
$1B upfront and ~
$300M in milestone payments. The deal would add Verve's lead gene-editing therapy targeting high LDL cholesterol to Lilly’s pipeline. An official announcement may come this week.
$SLRX – Nasdaq granted Salarius Pharma an extension to meet compliance. They must restore shareholder equity to
$2.5M by early July and meet the
$1.00 minimum bid price by early August or face delisting.
$BGSF – BGSF agreed to sell its Professional Division for
$99M in cash to INSPYR Solutions. Deal expected to close in H2 2025. CEO Beth Garvey and board member Cynthia Marshall to step down on July 1.
$RELI – Reliance Global has withdrawn its Form S-1, confirming it will not pursue the planned public offering.
$RGC – Still on watch as a potential multi-day runner.
